 
PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ — OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman’s statement to shareholders.
In the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the “Company”).
The Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients’ lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.
We have recruited a highly skilled management team with multi-year experience in medical cannabis, pharmaceutical development, corporate management and capital markets.
As we have stated in our 8-K filing of today, we are neither a party to the pending SEC action against a former adviser to the Company, nor is the Company alleged to have been a party to nor had any knowledge of the purported scheme by the former adviser, who is the subject of the SEC action.
The Company’s management is committed to and focused on our development programs which are continuing as per plan. These include inter alia, our current safety trial for our cannabis cream; the approval processes to initiate a safety trial for our oral disintegrating tablet and additional pipeline projects.
As a management team, we are committed to building value for our shareholders though professional, ethical and strategic management of a technology platform that we believe will bring improved health and quality of life to millions of patients around the world. We have recently announced the addition of our new Chief Scientific Officer and we continue to develop the resources we believe will bolster our endeavors in creating a great company.
Yours sincerely,
Dr. Stanley Hirsch
Chairman of the Board
OWC: About Us – Animation from One World Cannabis Ltd on Vimeo.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively ‘OWC’ or the ‘Company’) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
For more information visit:Â http://www.owcpharma.com/.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information::
Mordechai Bignitz , Chief Executive Officer – OWC Pharmaceutical Research Corp.
Email:Â [email protected]
Tel: +972-(0)3-7582659
